Department of Radiology, University of Piemonte Orientale, Piedmont, 28100 Novara, Italy.
Department of Radiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Tomography. 2022 Sep 23;8(5):2403-2410. doi: 10.3390/tomography8050199.
On 27 February 2021, the Food and Drug Administration(FDA) authorized the administration of the adenovirus-based Ad26.COV2-S vaccine (J&J-Janssen) for the prevention of COVID-19, a viral pandemic that, to date, has killed more than 5.5 million people. Performed during the early phase of the COVID-19 4th wave, this retrospective observational study aims to report the computerized tomography (CT) findings and intensive care unit admission rates of Ad26.COV2-S-vaccinated vs. unvaccinated COVID-19 patients. From the 1st to the 23rd of December 2021, all confirmed COVID-19 patients that had been subjected to chest non-contrast CT scan analysis were enrolled in the study. These were divided into Ad26.COV2.S-vaccinated (group 1) and unvaccinated patients (group 2). The RSNA severity score was calculated for each patient and correlated to CT findings and type of admission to a healthcare setting after CT-i.e., home care, ordinary hospitalization, sub-intensive care, and intensive care. Descriptive and inference statistical analyses were performed by comparing the data from the two groups. Data from a total of 71 patients were collected: 10 patients in group 1 (4M, 6F, mean age 63.5 years, SD ± 4.2) and 61 patients in group 2 (32M, 29F, mean age 64.7 years, SD ± 3.7). Statistical analysis showed lower values of RSNA severity in group 1 compared to group 2 (mean value 14.1 vs. 15.7, = 0.009, respectively). Furthermore, vaccinated patients were less frequently admitted to both sub-intensive and high-intensive care units than group 2, with an odds ratio of 0.45 [95%CI (0.01; 3.92)]. Ad26.COV2.S vaccination protects from severe COVID-19 based on CT severity scores. As a result, Ad26.COV2.S-vaccinated COVID-19 patients are more frequently admitted to home in comparison with unvaccinated patients.
2021 年 2 月 27 日，美国食品和药物管理局（FDA）授权使用基于腺病毒的 Ad26.COV2-S 疫苗（J&J-Janssen）预防 COVID-19，这是一种大流行病毒，迄今为止已导致超过 550 万人死亡。本回顾性观察研究在 COVID-19 第 4 波的早期阶段进行，旨在报告 Ad26.COV2-S 疫苗接种与未接种 COVID-19 患者的计算机断层扫描（CT）结果和重症监护病房（ICU）入院率。从 2021 年 12 月 1 日至 23 日，所有接受过胸部非对比 CT 扫描分析的确诊 COVID-19 患者均被纳入本研究。这些患者被分为 Ad26.COV2.S 疫苗接种组（第 1 组）和未接种组（第 2 组）。为每位患者计算了 RSNA 严重程度评分，并将其与 CT 结果和 CT 后入住医疗保健机构的类型相关联，例如家庭护理、普通住院、亚重症监护和重症监护。通过比较两组数据进行描述性和推理统计分析。共收集了 71 名患者的数据：第 1 组 10 名患者（4 名男性，6 名女性，平均年龄 63.5 岁，标准差±4.2），第 2 组 61 名患者（32 名男性，29 名女性，平均年龄 64.7 岁，标准差±3.7）。统计分析显示，第 1 组的 RSNA 严重程度值低于第 2 组（平均值 14.1 与 15.7， = 0.009）。此外，与第 2 组相比，接种疫苗的患者亚重症和重症监护病房的入院率较低，优势比为 0.45[95%CI（0.01；3.92）]。Ad26.COV2.S 疫苗接种可根据 CT 严重程度评分预防严重 COVID-19。因此，与未接种疫苗的患者相比，Ad26.COV2.S 接种的 COVID-19 患者更常被送回家中。
